Search research articles
Contact Us
Filters
Showing results (61-70 of 66) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 66 results.
JTO Clinical and Research Reports
|
January 3, 2022
Real-World Survival Outcomes Based on <i>EGFR</i> Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
Xue-Ning Yang, Hong-Hong Yan, Jun Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Jian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Annals of Translational Medicine
|
September 16, 2022
Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501)
You-Sheng Mao, Shu-Geng Gao, Yin Li, et al.
Nature Communications
|
November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Si-Yang Liu, Hua Bao, Qun Wang, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 66) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 66 results.
JTO Clinical and Research Reports
|
January 3, 2022
Real-World Survival Outcomes Based on <i>EGFR</i> Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
Xue-Ning Yang, Hong-Hong Yan, Jun Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Jian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Annals of Translational Medicine
|
September 16, 2022
Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501)
You-Sheng Mao, Shu-Geng Gao, Yin Li, et al.
Nature Communications
|
November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Si-Yang Liu, Hua Bao, Qun Wang, et al.
Page
of 7